Pasadena, Calif.-based Terray Therapeutics, which combines nanotechnology with artificial intelligence, has raised $60 million in a Series A funding round led by Seattle’s Madrona Venture Group. Terray’s chips are fit with millions of molecules that can be used for drug-target screening, with the resulting data fed into machine learning models. Madrona has historically backed tech companies but is increasingly investing in companies at the convergence of life and computer sciences, such as A-Alpha Bio, Ozette and Nautilus Biotechnology.
News Brief
